Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johann von Felden

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Current Opinion in Gastroenterology|February 27, 2020
New systemic agents for hepatocellular carcinoma: an update 2020Johann von Felden
Alimentary Pharmacology & Therapeutics|October 5, 2024
Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response PatientsJoao Gorgulho, Johann von Felden
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 16, 2020
Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular CarcinomaJohann von Felden, Augusto Villanueva
Hepatology Communications|September 14, 2020
Elevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular CarcinomaJohann von Felden, Henning Wege, Kornelius Schulze
Journal of Hepatology|October 6, 2019
Reply to: "Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014"Johann von Felden, Vincent Mallet, Sven Pischke
Discovery Medicine|October 4, 2017
Molecular profiling of liver cancer heterogeneityAmanda J Craig, Johann von Felden, Augusto Villanueva
Clinical Liver Disease|June 7, 2019
The Impact of Translational Research in HepatologyJohann von Felden, Amanda J Craig, Augusto Villanueva
Oncoscience|September 21, 2018
Role of circulating tumor DNA to help decision-making in hepatocellular carcinomaJohann von Felden, Amanda J Craig, Augusto Villanueva
International Journal of Clinical Pharmacology and Therapeutics|February 9, 2013
Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfateJohann von Felden, Matteo Montani, Kerstin Kessebohm, et al.
European Journal of Medical Genetics|August 21, 2021
Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomasHenning Wege, Kornelius Schulze, Johann von Felden, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Current Opinion in Gastroenterology|February 27, 2020
New systemic agents for hepatocellular carcinoma: an update 2020Johann von Felden
Alimentary Pharmacology & Therapeutics|October 5, 2024
Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response PatientsJoao Gorgulho, Johann von Felden
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 16, 2020
Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular CarcinomaJohann von Felden, Augusto Villanueva
Hepatology Communications|September 14, 2020
Elevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular CarcinomaJohann von Felden, Henning Wege, Kornelius Schulze
Journal of Hepatology|October 6, 2019
Reply to: "Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014"Johann von Felden, Vincent Mallet, Sven Pischke
Discovery Medicine|October 4, 2017
Molecular profiling of liver cancer heterogeneityAmanda J Craig, Johann von Felden, Augusto Villanueva
Clinical Liver Disease|June 7, 2019
The Impact of Translational Research in HepatologyJohann von Felden, Amanda J Craig, Augusto Villanueva
Oncoscience|September 21, 2018
Role of circulating tumor DNA to help decision-making in hepatocellular carcinomaJohann von Felden, Amanda J Craig, Augusto Villanueva
International Journal of Clinical Pharmacology and Therapeutics|February 9, 2013
Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfateJohann von Felden, Matteo Montani, Kerstin Kessebohm, et al.
European Journal of Medical Genetics|August 21, 2021
Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomasHenning Wege, Kornelius Schulze, Johann von Felden, et al.
Pageof 9